DJIA 8 Hour AllanTrend Model
VXX 8-Hour AllanTrends Model
If these two new signals hold, it would appear that an Intermediate term reversal is at hand.
A
A
"All in all, just another brick in the wall."-Benjamin Disraeli
"All in all, just another brick in the wall."-Benjamin Disraeli
Trading Notes
It was about this time in early November, 47 years ago, when our lives were so innocently headed for the single most devastating shock to our society in modern history. To be followed on an even grander scale just 38 years after that, September 11, 2001. So when I saw the market start to sell off this afternoon, in quiet, anonymous bidding, it occurred to me that this just might be how the next one starts. An innocuous late day sell off that we have been conditioned by now to ignore, a few 60 minute models flipping SHORT, again, something so meaningless lately we hardly ever report it. Then even quieter trading into a quiet close and no once even considers that it may be different this time.
My worlds were rocked in 1963 and again in 2001. One event shaped the first half of my life. The second event is shaping the rest of my life. Where-ever we are at any one time in this 4th dimensional continuum of being, it remains invisible to these third dimensional eyes. As it must be.
But there is a tether that brings it all together. The financial markets and how we as a society behave as one was described by Robert Precther in his book, "Socionomics." Just a few short weeks ago, Prechter wrote that we were engulfed in the greatest financial top of all time. Each day that it doesn't arrive, is just one more day that it is closer. So when I see an innocuous little sell-off creeping into a late and largely forgettable Tuesday afternoon, I stop for a moment, think back 9 and 47 years ago and then start paying a little more attention.
A
These three names are HIGHLY SPECULATIVE and depart from the usually conservative nature of our Trend Following methodology. It's possible that all three can be cut in half in week, a day, or an hour. Conversely, all three could soar, doubling or tripling, or even more in a week, a day, or an hour. HOW we make money here is no less important then MAKING MONEY. We've seen that the Trend Models work i.e. they make money, so we are allowed to take a flier, or two, or in this case three, every once in awhile.
NanoViricides is on the precipice of a mammoth breakthrough — they hold what is likely the cure to all worldly viruses. In combination with that, NanoViricides holds a virtual license to profit through the FDA voucher system.
Best of all, the story hasn’t hit the mainstream media yet and your opportunity to join this transformational move is still here.
Incidentally, we know that small biotechs are particularly subject to irrational vacillations. It’s inevitable that this company will be bouncing in weeks and months to come. Right now, however, almost nobody knows what I’ve said in this report. If you plan to buy, be patient and pick up stock when prices are down.
If you jump in and bid the price of this small cap up too high, it will attract attention and the bargains could be gone for good. And please don’t settle for short-term gains of a few hundred percent. The long-run potential of this technology is far, far greater — and today’s opportunity truly is once in a lifetime.
Next on the list is HIV. Back in 2008, spectacular results were announced for HIVCide in Israel. Based on the findings there, it was suggested that the company had attained a “functional cure.” This is due to the drug’s ability to decrease the amount of circulating virus and to suppress the virus exiting infected cells in which it was sequestered. HIVCide should allow an affected person to live an essentially normal life, as virus load is so low that the virus cannot be transmitted.
NanoViricides, Inc. Reports Dramatically Extended Survival for FluCide™ Treated Animals in an Influenza Lethality Study
WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reported today that its FluCide™ drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu® treated animals.
Animals treated with the best of the optimized FluCide nanoviricide drug candidates survived greater than twice as long (18.1 days) as opposed to the animals treated with Tamiflu (only 7.8 days). In a previous study, the Company had reported that animals treated with the then best anti-influenza nanoviricides survived for as long as 13.9 days in the same animal model.
We are extremely happy with the substantially improved performance achieved in our optimization efforts,” said Randall Barton, PhD, Chief Scientific Officer of the Company, adding, “An increase in dosage is now likely to lead to total survival even in this completely lethal virus challenge model.”
“Our Influenza Program is progressing satisfactorily towards a pre-IND submission to the FDA in the near future,” said Eugene Seymour, MD, MPH, CEO of the Company.